Cartesian Therapeutics (RNAC) Equity Average (2016 - 2026)
Cartesian Therapeutics (RNAC) has disclosed Equity Average for 11 consecutive years, with -$137.2 million as the latest value for Q1 2026.
- For Q1 2026, Equity Average fell 859.6% year-over-year to -$137.2 million; the TTM value through Mar 2026 reached -$137.2 million, down 859.6%, while the annual FY2025 figure was -$66.5 million, 70.24% up from the prior year.
- Equity Average hit -$137.2 million in Q1 2026 for Cartesian Therapeutics, down from -$81.0 million in the prior quarter.
- Across five years, Equity Average topped out at $89.4 million in Q4 2022 and bottomed at -$278.5 million in Q1 2024.
- Average Equity Average over 5 years is -$22.9 million, with a median of -$12.2 million recorded in 2025.
- Year-over-year, Equity Average skyrocketed 4615.96% in 2022 and then crashed 2579.07% in 2025.
- Cartesian Therapeutics' Equity Average stood at $89.4 million in 2022, then plummeted by 312.52% to -$189.9 million in 2023, then soared by 98.41% to -$3.0 million in 2024, then plummeted by 2579.07% to -$81.0 million in 2025, then plummeted by 69.27% to -$137.2 million in 2026.
- According to Business Quant data, Equity Average over the past three periods came in at -$137.2 million, -$81.0 million, and -$19.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.